I agree its frustrating and there seems to have been a serial seller over the past few months who has recently been exhausted.
I also believe they had good reason to place the word imminent in their October presentation. The ASX require factual evidence behind any claim made by a public company.
The reality is theres bureaucratic levels within organisations which BGT must wade through before a deal is struck, even if internal groups are willing to move forward.
The Bio-Gene story will become a lot more blue sky to investors and funds once deal/s arrive and sentiment shifts.
BGT Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
